期刊文献+

吉非替尼联合放疗治疗非小细胞肺癌脑转移的效果分析 被引量:4

在线阅读 下载PDF
导出
摘要 目的:研究用吉非替尼联合放疗对非小细胞肺癌脑转移患者进行治疗的临床效果。方法:将2017年3月至2018年3月四川大学华西广安医院收治的60例非小细胞肺癌脑转移患者作为研究对象。将其随机分为control组和experimental组。对两组患者均进行全脑放疗。在此基础上,为experimental组患者加用吉非替尼进行治疗。然后对比两组患者治疗的有效率及不良反应的发生率。结果:control组患者治疗的有效率为80%,experimental组患者治疗的有效率为96.67%,组间差异有统计学意义(P <0.05)。在治疗期间,control组患者不良反应的发生率为73.33%,experimental组患者不良反应的发生率为46.67%,组间差异有统计学意义(P <0.05)。结论:用吉非替尼联合放疗对非小细胞肺癌脑转移患者进行治疗的临床效果较好,能够降低其不良反应的发生率。
作者 王颖
出处 《当代医药论丛》 2018年第24期58-59,共2页
  • 相关文献

参考文献5

二级参考文献92

  • 1王燕,王颖,王彬,王子平,张湘茹,储大同,孙燕.吉非替尼治疗非小细胞肺癌脑转移的初步结果[J].中国肺癌杂志,2006,9(5):447-451. 被引量:33
  • 2Youlden DR,Cramb SM,Baade PD,et al. The International Epi-demiology of Lung Cancer : geographical distribution and seculartrends[J]. J Thorac Oncolr2008,3(8) .-819-831.
  • 3Carbone DP,Ding K,Roder H, et al. Prognostic and predictiverole of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in theNCIC Clinical Trials Group BR. 21 trial [J]. J Thorac Oncol,2012,7C11):1653-1660.
  • 4Zhou S, Ren S, Yan L, et al. Clinical efficacy of erlotinib in pa-tients previously treated for advanced non-small cell lung cancer[J]. Respirology,2009,14(5) :709~715.
  • 5Weber B, Winterdahl M,Memon A,et al. Erlotinib accumulationin brain metastases from non-small cell lung cancer : visualizationby positron emission tomography in a patient harboring a muta-tion in the epidermal growth factor receptor[J]. J Thorac Oncol,2011,6(7):1287-1289.
  • 6Zhao J,Chen M, Zhong W, et al. Cerebrospinal fluid concentra-tions of gefitinib in patients with lung adenocarcinoma [J ]. ClinLung Cancer,2013 ,14(2) : 188-193.
  • 7Li Z,Lu J, Zhao Y, et al. The retrospective analysis of the fre-quency of EGFR mutations and efficacy of gefitinib in NSCLCpatients with brain metastases [ J ]. J Clin Oncol,2011, 29:el8065.
  • 8Iuchi T,Shingyoji M,Sakaida T,et al. Phase II trial of gefitinibalone without radiation therapy for Japanese patients with brainmetastases from EGFR-mutant lung adenocarcinoma [ J ]. Lungcancer,2013,82(2) :282-287.
  • 9Park SJ, Kim HT,Lee DH, et al. Efficacy of epidermal growth,factor receptor tyrosine kinase inhibitors for brain metastasis innon-small cell lung cancer patients harboring either exon 19 or 21mutation[J]. Lung cancer, 2012 ,77(3) : 556-560.
  • 10Wu YL, Zhou C,Cheng Y, et al. Erlotinib as second-line treat-ment in pdatients with advanced non-small-cell lung cancer andasymptomatic brain metastases: a phase [[ study (CTONG-0803)[J]. Ann Oncol,2013 ,24(4) :993-999.

共引文献93

同被引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部